APP and Alzheimer disease: In the future, screening of ABCA7 PTC mutations in clinical practice might improve AD diagnosis and risk prediction, mainly in familial AD patients negative for mutations in APP, PSEN1 and PSEN2. However, further research is necessary to elucidate both the pathogenicity and the disease penetrance of individual ABCA7 PTC mutations.